Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.57 |
| ▸ | SYK | P43405 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.47 |
| ▸ | AURKA | O14965 | 2/20 | 0.47 |
| ▸ | PLK1 | P53350 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | FER | P16591 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | STK4 | Q13043 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30041532 | 1.00 | EGFR (0.57) | EGFRSYKNFKB1KMT2AERBB2 | |
| SCHEMBL21596304 | 0.83 | PIN1 (0.55) | EGFRSYKNFKB1KMT2AAURKA | |
| SCHEMBL30379431 | 0.83 | PIN1 (0.55) | EGFRSYKNFKB1KMT2AAURKA | |
| SCHEMBL9945499 | 0.82 | EGFR (0.64) | EGFRSYKNFKB1AURKALMNA | |
| SCHEMBL9945497 | 0.82 | EGFR (0.64) | EGFRNFKB1AURKALMNAPOLB | |
| SCHEMBL30394764 | 0.82 | EGFR (0.64) | EGFRNFKB1AURKALMNAPOLB | |
| SCHEMBL2300114 | 0.80 | SYK (0.50) | EGFRSYKERBB2 | |
| SCHEMBL12518356 | 0.80 | AURKA (0.72) | EGFRSYKNFKB1AURKAFER | |
| SCHEMBL13606356 | 0.80 | EGFR (0.61) | EGFRSYKNFKB1AURKAPOLB | |
| SCHEMBL19958510 | 0.80 | EGFR (0.61) | EGFRSYKNFKB1ERBB2AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230137932-A1 | CYANO-PYRIMIDINE INHIBITORS OF EGFR/HER2 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-05-04 | — | — | US | disclosed |
| EP-4087571-A1 | CYANO-PYRIMIDINE INHIBITORS OF EGFR/HER2 | Dana-Farber Cancer Institute, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230137932-A1 | CYANO-PYRIMIDINE INHIBITORS OF EGFR/HER2 | ERBB2, EGFR, ERBB3 | EGFR 2/4885SYK 472/4885NFKB1 3171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.